Galapagos Past Earnings Performance

Past criteria checks 0/6

Galapagos's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 27.6% per year.

Key information

-6.3%

Earnings growth rate

-9.0%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate-27.6%
Return on equity-2.1%
Net Margin-23.3%
Next Earnings Update12 Feb 2025

Recent past performance updates

Recent updates

Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be

Apr 19
Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be

Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business

Jan 03
Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business

Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S

Jul 18
Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S

€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

May 06
€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results

Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Mar 29
Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation

Revenue & Expenses Breakdown

How Galapagos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTAM:GLPG Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24260-611320
30 Jun 24261321320
31 Mar 24244311300
31 Dec 23240-41260
30 Sep 23544-1532720
30 Jun 2386-4663-223
31 Mar 23163-691030
31 Dec 22241-711390
30 Sep 225776262223
30 Jun 22505-81230223
31 Mar 22507-1262190
31 Dec 21234-1211320
30 Sep 21474-2011950
30 Jun 21537-2192020
31 Mar 21488-2721960
31 Dec 20478-3111850
30 Sep 20455-3681680
30 Jun 20972751570
31 Mar 209481451200
31 Dec 19835149970
30 Sep 19865280740
30 Jun 19324-66520
31 Mar 19314-41440
31 Dec 18318-29400
30 Sep 18255-743496
30 Jun 18185-1263096
31 Mar 18161-1392896
31 Dec 17156-116270
30 Sep 17193-402668
30 Jun 17176-272668
31 Mar 1717742568
31 Dec 16152542468
30 Sep 1678-492349
30 Jun 1672-522249
31 Mar 1655-682149
31 Dec 1561-1182049
30 Sep 1575-721835
30 Jun 1582-571735
31 Mar 1588-441535
31 Dec 1490-371535
30 Sep 1486-32146
30 Jun 1492-251413
31 Mar 1494-211420
31 Dec 1397-171427

Quality Earnings: GLPG is currently unprofitable.

Growing Profit Margin: GLPG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GLPG is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.

Accelerating Growth: Unable to compare GLPG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GLPG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: GLPG has a negative Return on Equity (-2.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies